Dr. Jess F. Armor, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Oklahoma College of Medicine (1999)
- Years since graduation
- 27
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 479
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1999Medical school: University of Oklahoma College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
OK license 22938
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- O U Medical Center Oklahoma City, OK
- Mercy Hospital Oklahoma City, Inc Oklahoma City, OK
- Oklahoma Heart Hospital, LLC Oklahoma City, OK
- Integris Health Woodward Hospital Woodward, OK
- Harper County Community Hospital Buffalo, OK
Medical groups
- Mercy Clinic Oklahoma Communities (649 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 479
- Services billed
- 5,293
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Insertion of needle into vein for collection of blood sample | 1,593 | 386 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 1,499 | 377 |
| Established patient office or other outpatient visit, 30-39 minutes | 617 | 345 |
| Established patient office or other outpatient visit, 40-54 minutes | 380 | 151 |
| New patient office or other outpatient visit, 60-74 minutes | 68 | 68 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 60 | 27 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 44 | 40 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 40 | 19 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 33 | 14 |
| Established patient office or other outpatient visit, 20-29 minutes | 25 | 23 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Oklahoma City, OK | 124 |
| Gabapentin Other prescribers in Oklahoma City, OK | 111 |
| Lenalidomide | 106 |
| Levothyroxine Sodium Other prescribers in Oklahoma City, OK | 96 |
| Prednisone Other prescribers in Oklahoma City, OK | 84 |
| Ondansetron Odt (ondansetron) Other prescribers in Oklahoma City, OK | 81 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Oklahoma City, OK | 78 |
| Abiraterone Acetate | 74 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Oklahoma City, OK | 70 |
| Oxycodone Hcl Other prescribers in Oklahoma City, OK | 69 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 36 payments worth $1,558 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $1,071 |
|---|---|
| Beone Medicines USA, Inc. | $190 |
| AstraZeneca Pharmaceuticals LP | $99.94 |
| Pfizer Inc. | $73.16 |
| Genentech USA, Inc. | $53.45 |
| Merck Sharp & Dohme LLC | $29.36 |
| Astellas Pharma US Inc | $26.56 |
| Beigene USA, Inc. | $14.49 |
| Long term medical supply or device loan | $1,000 |
|---|---|
| Food and Beverage | $332 |
| Education | $227 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Feb 24, 2025 | Education LYNPARZA · Oncology · in-kind Company’s descriptionEducational Item | $99.94 |
| Novartis Pharmaceuticals Corporation Jan 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Feb 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Mar 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation May 15, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Apr 24, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Jun 12, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Jul 25, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Aug 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Oct 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
All 18 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Dec 30, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Nov 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Pfizer Inc. Nov 10, 2025 | Education IBRANCE · ONCOLOGY · in-kind | $30.65 |
| Novartis Pharmaceuticals Corporation Oct 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Sep 19, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Pfizer Inc. Sep 9, 2025 | Education IBRANCE · ONCOLOGY · in-kind | $14.17 |
| Pfizer Inc. Sep 9, 2025 | Education IBRANCE · ONCOLOGY · in-kind | $14.17 |
| Novartis Pharmaceuticals Corporation Aug 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Pfizer Inc. Aug 7, 2025 | Education IBRANCE · ONCOLOGY · in-kind | $14.17 |
| Genentech USA, Inc. Aug 1, 2025 | Education in-kind | $53.45 |
| Novartis Pharmaceuticals Corporation Jul 25, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Jun 12, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation May 15, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Apr 24, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Mar 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| AstraZeneca Pharmaceuticals LP Feb 24, 2025 | Education LYNPARZA · Oncology · in-kind Company’s descriptionEducational Item | $99.94 |
| Novartis Pharmaceuticals Corporation Feb 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Jan 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.